{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-043544","form_type":"8-K","ticker":"AKTX","cik":"0001541157","company_name":"Akari Therapeutics Plc","filed_at":"2025-03-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.953398+00:00","generated_at":"2026-05-25T17:42:42.355258+00:00","sec_items":["1.01","3.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Akari Therapeutics raises ~$7.1M via ADS/warrant offering with board participation","bullets":["Gross proceeds ~$7.1M from sale of 6,637,626 ADS units (or prefunded warrants) plus Series A/B warrants; includes $1M note termination by Chairman.","ADS unit purchase price: $0.87 plus $0.25–$0.3125 premium per tier; warrants exercisable at $0.87.","Series A warrants expire 1 year, Series B warrants expire 5 years from closing.","Chairman Dr. Hoyoung Huh, CEO Dr. Samir Patel, and all board members participating; $1M note terminated.","Proceeds for working capital; resale registration statement to be filed within 60 days of closing (expected March 5)."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-043544","json":"https://secwatch.observer/filing/0001193125-25-043544.json","markdown":"https://secwatch.observer/filing/0001193125-25-043544.md","text":"https://secwatch.observer/filing/0001193125-25-043544.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1541157/000119312525043544/0001193125-25-043544-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1541157/000119312525043544/d803084d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-25T17:42:42.355258+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}